Interests: Advanced heart failure; Sex differences in heart failure; Health equity
Special Issue Information
Among the more than 6 million adults in the United States with heart failure, a subset of them will develop advanced heart failure despite our best efforts. Advanced therapies including durable mechanical circulatory support and heart transplantation may be available options for certain patients.
Over the last decade, there have been significant innovations and advances in the approach to advanced heart failure. Results of the MOMENTUM 3 trial suggest that short-term outcomes with the HeartMate 3 left ventricular assist device (LVAD) are similar to heart transplantation. Temporary mechanical circulatory support has also been increasingly used as a bridge to transplantation. The change in the heart transplant organ allocation system that went into effect in October 2018 has had impact on treatment strategies particularly for certain subgroups of individuals. Additionally, strategies have been introduced to increase the donor pool such as transplantation from Hepatitis-C-positive donors as well as donation after circulatory death (DCD) heart transplantation.
In light of the recent advances and changing landscape of LVAD technology and heart transplantation, we introduce this series of concise reviews to highlight the innovation of the field and contemporary management of these patients in the current day.
We would like to invite experts in the field to write comprehensive reviews (3000 to 5000 words) covering the following topics:
- Risk Factors and Management of Primary Graft Dysfunction
- Strategies for expanding the donor pool for heart transplantation (i.e. use of DCD and Hepatitis C positive donors)
- Impact of the new heart transplant allocation system
- Considerations for dual-organ transplantation
- Future technologies and directions for durable left ventricular assist devices
- Management of pulmonary hypertension in patients on left ventricular assist device support
- Improving access to heart transplantation for under-represented groups - Palliative care and approach for patients who are not candidates for advanced therapies
Dr. Ersilia M. DeFilippis
Manuscript Submission Information
Manuscripts should be submitted online at https://rcm.imrpress.org by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on theInstructions for Authorspage. Reviews in Cardiovascular Medicine is an international peer-reviewed open access quarterly journal published by IMR Press.